Navigation Links
Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
Date:12/10/2008

($242 million net of cash). In the six month period following closing, Valeant will fund an escrow account of $35 million, which will be subject to indemnification claims from Valeant for a period of eighteen months following closing. The transaction is expected to be accretive in 2009. Additionally, Valeant will pay future milestones, based predominately on the achievement of approval and commercial targets for certain pipeline products still in development.

The transaction was approved by the boards of directors for both companies and is subject to customary closing conditions, including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended. The transaction is expected to close at year end.

"This acquisition grows our scale and capabilities in dermatology thus solidifying Valeant's future as a leading company in the development and commercialization of dermatology medications," stated J. Michael Pearson, chairman and chief executive officer. "Gordon Dow, the founder of Dow Pharmaceutical Sciences, and his team are highly regarded with innovative formulation and development expertise, exemplified by having worked on ten dermatology approvals from the FDA in the past few years and with projects underway in eight of the top ten dermatology diagnoses. We are excited that they will be joining the Valeant team as we believe the synergies between our newly acquired Coria franchise and Dow's business will provide sustainable growth for many years to come."

Conference Call and Webcast and Presentation:

Valeant will host a conference call today at 11:00 a.m. EST (8:00 a.m. PST) to discuss the transaction. The dial-in number to participate on this call is (877) 295-5743, confirmation code 76913148. International callers should dial (973) 200-3961, confirmation code 76913148. A replay will be available approxim
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DFB Sells Coria Labs to Valeant Pharmaceuticals
2. Quantros Acquires MEDMARX(R) from United States Pharmacopeia (USP)
3. Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM)
4. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
5. Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products Neurodegenerative Diagnostics
6. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
7. Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
8. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
9. BBM Announces Offer to Acquire YM BioSciences Inc.
10. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
11. Diagnostic Imaging - Enters Purchase Agreement to Acquire Teleradiology Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Canada (PRWEB) August 22, 2014 ... in model organisms can be accelerated by exome ... and manufacturing technologies, the custom SeqCap EZ Developer ... research. , Mr. Watson will additionally present how ... with commercially available human and mouse exome kits. ...
(Date:8/21/2014)... research group at the Institute for Molecular Medicine ... Stockholm, has developed a novel "man and machine" ... innovative diagnostic aid was described in PLOS ... method is based on computer vision algorithms similar ... with visualization of only the diagnostically most relevant ...
(Date:8/21/2014)... 2014 His Majesty Willem-Alexander, King of ... Court of His Majesty Willem-Alexander, King of the Netherlands, ... Opening of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol ... The King will take part in the Grand Opening ... 11 a.m.-12:20 p.m. and tour the plant. POET-DSM is ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary Dynamics ... Jeffrey Epstein VI Foundation , have shown that the ... elimination. These aggressive cells are the driver mutations that drive ... of what to look for when examining tumors, comes at ... can be extracted from biopsy, it,s very difficult to know ...
Breaking Biology Technology:Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2A novel 'man and machine' decision support system makes malaria diagnostics more effective 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2
... 2011 Landauer, Inc. (NYSE: LDR ... monitoring and the leading domestic provider of outsourced medical physics ... quarter ended March 31, 2011.   Fiscal 2011 ... to $32.3 million on contribution from Medical Physics segment and ...
... N.J., May 3, 2011 BioNeutral Group, Inc. ... today announced that it has signed on to ... disinfectant technology to the infection control professionals attending ... in Infection Control and Epidemiology) ( www.apic.org ). ...
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company dedicated to ... financial results for the first quarter ended March 31, 2011. ... 2011, VIVUS reported a net loss of $9.9 million or $0.12 ... or $0.23 per share for the first quarter of 2010. The ...
Cached Biology Technology:Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 2Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 3Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 4Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 5Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 6Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 7Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 8Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 9Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 10Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 11Landauer, Inc. Reports Fiscal 2011 Second Quarter Results 12BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 2BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 3BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review 4VIVUS Reports First Quarter 2011 Financial Results 2VIVUS Reports First Quarter 2011 Financial Results 3VIVUS Reports First Quarter 2011 Financial Results 4VIVUS Reports First Quarter 2011 Financial Results 5
(Date:8/22/2014)... presented at the 29th Annual International Papillomavirus Conference ... Therapeutics Inc. combats three types of human papillomavirus, ... all cervical cancer. , When tested in several ... of HPV-16, HPV-18 and HPV-11 cells, according to ... who presented the findings at the Seattle conference. ...
(Date:8/22/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Grant Writing Seminar & Practical Exercises Workshop which will ... Maryland from August 25-26, 2014. These awards are ... research scientists from underrepresented groups in the the FASEB ... year MARC conferred 11 awards totaling $20,350. , The ...
(Date:8/22/2014)... German . ... are fixated in a way so as to align ... and Fudan University researchers are planning on looking into ... findings are being published today in the scientific journal ... sensitive molecules. Everyone knows that at least from ...
Breaking Biology News(10 mins):Proteins: New class of materials discovered 2
... disease or muscle loss that direct the body to ... a weakened condition. That,s not hard to do thanks ... developed an organic substance that attracts and supports cells ... into problem areas. This development, published online in ...
... (ACS) News Service Weekly PressPac with news from ACS, 34 ... the individual journal or the American Chemical Society as the ... RELEASE Clothing to crow about: Chicken feather suits ... may snuggle up in warm, cozy sweats made of chicken ...
... Using new technologies that make it easier to sequence ... Comprehensive Cancer Center have identified a series of genes ... each other. These recurrent gene fusions are thought to ... develop. The gene fusions discovered could potentially serve ...
Cached Biology News:'Smart scaffolds' may help heal broken hearts 2American Chemical Society's Weekly PressPac -- Jan. 7, 2009 2American Chemical Society's Weekly PressPac -- Jan. 7, 2009 3American Chemical Society's Weekly PressPac -- Jan. 7, 2009 4American Chemical Society's Weekly PressPac -- Jan. 7, 2009 5American Chemical Society's Weekly PressPac -- Jan. 7, 2009 6American Chemical Society's Weekly PressPac -- Jan. 7, 2009 7American Chemical Society's Weekly PressPac -- Jan. 7, 2009 8American Chemical Society's Weekly PressPac -- Jan. 7, 2009 9U-M researchers discover new genes that fuse in cancer 2
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
... Goat anti-Human Alpha 1 Acid ... azide Goats were immunized ... glycoprotein in Freund's adjuvant. ... absorbed to ensure specificity. ...
Purified Mouse anti-Hu p120 Catenin (pT916) Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: